nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.11.2015 | Original Article

Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo

verfasst von: K. M. Hare, K. Grimwood, A. B. Chang, M. D. Chatfield, P. C. Valery, A. J. Leach, H. C. Smith-Vaughan, P. S. Morris, C. A. Byrnes, P. J. Torzillo, A. C. Cheng

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Although long-term azithromycin decreases exacerbation frequency in bronchiectasis, increased macrolide resistance is concerning. We investigated macrolide resistance determinants in a secondary analysis of a multicenter randomized controlled trial. Indigenous Australian children living in remote regions and urban New Zealand Māori and Pacific Islander children with bronchiectasis were randomized to weekly azithromycin (30 mg/kg) or placebo for up to 24 months and followed post-intervention for up to 12 months. Nurses administered and recorded medications given and collected nasopharyngeal swabs 3–6 monthly for culture and antimicrobial susceptibility testing. Nasopharyngeal carriage of Haemophilus influenzae and Moraxella catarrhalis was significantly lower in azithromycin compared to placebo groups, while macrolide-resistant Streptococcus pneumoniae and Staphylococcus aureus carriage was significantly higher. Australian children, compared to New Zealand children, had higher carriage overall, significantly higher carriage of macrolide-resistant bacteria at baseline (16/38 versus 2/40 children) and during the intervention (69/152 versus 22/239 swabs), and lower mean adherence to study medication (63 % versus 92 %). Adherence ≥70 % (versus <70 %) in the Australian azithromycin group was associated with lower carriage of any pathogen [odds ratio (OR) 0.19, 95 % confidence interval (CI) 0.07–0.53] and fewer macrolide-resistant pathogens (OR 0.34, 95 % CI 0.14–0.81). Post-intervention (median 6 months), macrolide resistance in S. pneumoniae declined significantly in the azithromycin group, from 79 % (11/14) to 7 % (1/14) of positive swabs, but S. aureus strains remained 100 % macrolide resistant. Azithromycin treatment, the Australian remote setting, and adherence <70 % were significant independent determinants of macrolide resistance in children with bronchiectasis. Adherence to treatment may limit macrolide resistance by suppressing carriage.

Nur mit Berechtigung zugänglich

Singleton RJ, Valery PC, Morris P, Byrnes CA, Grimwood K, Redding G, Torzillo PJ, McCallum G, Chikoyak L, Mobberly C, Holman RC, Chang AB (2014) Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol 49(2):189–200CrossRefPubMed

Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R (2009) Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 34(4):843–849CrossRefPubMed

Steinfort DP, Brady S, Weisinger HS, Einsiedel L (2008) Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 102(4):574–578CrossRefPubMed

Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380(9842):660–667CrossRefPubMed

Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309(12):1251–1259CrossRefPubMed

Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD (2013) Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 309(12):1260–1267CrossRefPubMed

Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, Masters IB, Diaz A, McCallum GB, Mobberley C, Tjhung I, Hare KM, Ware RS, Chang AB (2013) Long-term azithromycin for indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 1(8):610–620CrossRefPubMed

Mak DB (2006) Better late than never: a national approach to trachoma control. Med J Aust 184(10):487–488PubMed

Bowden FJ, Fethers K (2008) “Let’s not talk about sex”: reconsidering the public health approach to sexually transmissible infections in remote Indigenous populations in Australia. Med J Aust 188(3):182–184PubMed

10.

Valery PC, Morris PS, Grimwood K, Torzillo PJ, Byrnes CA, Masters IB, Bauert PA, McCallum GB, Mobberly C, Chang AB (2012) Azithromycin for indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Pediatr 12:122PubMedCentralCrossRefPubMed

11.

DiMatteo MR (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42(3):200–209CrossRefPubMed

12.

Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL (2006) A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 5(3):177–185CrossRefPubMed

13.

Hare KM, Grimwood K, Leach AJ, Smith-Vaughan H, Torzillo PJ, Morris PS, Chang AB (2010) Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr 157(6):1001–1005CrossRefPubMed

14.

Bell SM, Pham JN, Newton PJ, Nguyen TT (2014) Antibiotic sensitivity testing by the CDS method. A manual for medical and veterinary laboratories. Seventh edition. Available online at: http://cdstest.net/manual/

15.

Bauer AW, Kirby WM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. Tech Bull Regist Med Technol 36(3):49–52PubMed

16.

Hare KM, Singleton RJ, Grimwood K, Valery PC, Cheng AC, Morris PS, Leach AJ, Smith-Vaughan HC, Chatfield M, Redding G, Reasonover AL, McCallum GB, Chikoyak L, McDonald MI, Brown N, Torzillo PJ, Chang AB (2013) Longitudinal nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in indigenous Australian and Alaska native children with bronchiectasis. PLoS One 8(8):e70478PubMedCentralCrossRefPubMed

17.

Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD (1997) A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 24(3):356–362CrossRefPubMed

18.

Morris PS, Gadil G, McCallum GB, Wilson CA, Smith-Vaughan HC, Torzillo P, Leach AJ (2010) Single-dose azithromycin versus seven days of amoxycillin in the treatment of acute otitis media in Aboriginal children (AATAAC): a double blind, randomised controlled trial. Med J Aust 192(1):24–29PubMed

19.

Hare KM, Leach AJ, Morris PS, Smith-Vaughan H, Torzillo P, Bauert P, Cheng AC, McDonald MI, Brown N, Chang AB, Grimwood K (2012) Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in indigenous Australian children with non-cystic fibrosis bronchiectasis. Int J Antimicrob Agents 40(4):365–369CrossRefPubMed

20.

Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD, Sá-Leão R, Scott JA, Nohynek H, O’Brien KL; WHO Pneumococcal Carriage Working Group (2013) Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine 32(1):165–179CrossRefPubMed

21.

Flanagan PG, Paull A (1998) Carbon dioxide requirements of Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 42(5):669–670CrossRefPubMed

22.

Edwards EA, Asher MI, Byrnes CA (2003) Paediatric bronchiectasis in the twenty-first century: experience of a tertiary children’s hospital in New Zealand. J Paediatr Child Health 39(2):111–117CrossRefPubMed

23.

Munro KA, Reed PW, Joyce H, Perry D, Twiss J, Byrnes CA, Edwards EA (2011) Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression? Pediatr Pulmonol 46(2):131–138CrossRefPubMed

24.

Mills N, Best EJ, Murdoch D, Souter M, Neeff M, Anderson T, Salkeld L, Ahmad Z, Mahadevan M, Barber C, Brown C, Walker C, Walls T (2015) What is behind the ear drum? The microbiology of otitis media and the nasopharyngeal flora in children in the era of pneumococcal vaccination. J Paediatr Child Health 51(3):300–306PubMedCentralCrossRefPubMed

25.

Pingault NM, Bowman JM, Lehmann D, Riley TV (2010) Antimicrobial susceptibility of Moraxella catarrhalis isolated from children in Kalgoorlie-Boulder, Western Australia. Pathology 42(3):273–279CrossRefPubMed

26.

Peric M, Bozdogan B, Jacobs MR, Appelbaum PC (2003) Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 47(3):1017–1022PubMedCentralCrossRefPubMed

27.

Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz B, Mfinanga SG, West S (2013) Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 56(11):1519–1526CrossRefPubMed

28.

Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, Zhou Z, House J, Ray K, Porco T, Rutar T, Keenan J, Lietman TM, Gaynor BD (2010) The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 51(5):571–574CrossRefPubMed

29.

Maher MC, Alemayehu W, Lakew T, Gaynor BD, Haug S, Cevallos V, Keenan JD, Lietman TM, Porco TC (2012) The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. PLoS One 7(1):e29407PubMedCentralCrossRefPubMed

30.

Hansen CR, Pressler T, Hoiby N, Johansen HK (2009) Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros 8(1):58–62CrossRefPubMed

31.

Phaff SJ, Tiddens HA, Verbrugh HA, Ott A (2006) Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 57(4):741–746CrossRefPubMed

32.

Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclercq R (2003) High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187(11):1709–1716CrossRefPubMed

33.

Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK (2007) Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26(1):8–12CrossRefPubMed

34.

McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM (2013) Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS One 8(7):e69763PubMedCentralCrossRefPubMed

35.

Horváth A, Dobay O, Kardos S, Ghidán Á, Tóth Á, Pászti J, Ungvári E, Horváth P, Nagy K, Zissman S, Füzi M (2012) Varying fitness cost associated with resistance to fluoroquinolones governs clonal dynamic of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 31(8):2029–2036CrossRefPubMed

36.

Nielsen KL, Pedersen TM, Udekwu KI, Petersen A, Skov RL, Hansen LH, Hughes D, Frimodt-Møller N (2012) Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic. J Antimicrob Chemother 67(6):1325–1332CrossRefPubMed

37.

Tu YK, Gunnell D, Gilthorpe MS (2008) Simpson’s Paradox, Lord’s Paradox, and Suppression Effects are the same phenomenon—the reversal paradox. Emerg Themes Epidemiol 5:2PubMedCentralCrossRefPubMed

38.

Assmann SF, Pocock SJ, Enos LE, Kasten LE (2000) Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355(9209):1064–1069CrossRefPubMed

39.

Lynch JP 3rd, Zhanel GG (2010) Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 16(3):217–225PubMed

40.

Tong SY, Varrone L, Chatfield MD, Beaman M, Giffard PM (2015) Progressive increase in community-associated methicillin-resistant Staphylococcus aureus in Indigenous populations in northern Australia from 1993 to 2012. Epidemiol Infect 143:1519–1523CrossRefPubMed

41.

Hare KM, Stubbs E, Beissbarth J, Morris PS, Leach AJ (2010) Swab transport in Amies gel followed by frozen storage in skim milk tryptone glucose glycerol broth (STGGB) for studies of respiratory bacterial pathogens. J Microbiol Methods 81(3):253–255CrossRefPubMed

42.

Hare KM, Smith-Vaughan HC, Leach AJ (2011) Viability of respiratory pathogens cultured from nasopharyngeal swabs stored for up to 12 years at −70°C in skim milk tryptone glucose glycerol broth. J Microbiol Methods 86(3):364–367CrossRefPubMed

43.

Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H (2007) Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369(9560):482–490CrossRefPubMed

Titel: Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo
verfasst von: K. M. Hare
K. Grimwood
A. B. Chang
M. D. Chatfield
P. C. Valery
A. J. Leach
H. C. Smith-Vaughan
P. S. Morris
C. A. Byrnes
P. J. Torzillo
A. C. Cheng
Publikationsdatum: 01.11.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2015
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-015-2480-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain

Rapid detection of carbapenemase activity: benefits and weaknesses of MALDI-TOF MS

Contribution of IL6 −174 G>C and IL1B +3954 C>T polymorphisms to congenital infection with Toxoplasma gondii

Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain